
TY  - JOUR
C7  - e28049
TI  - ABSTRACTS
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 66
IS  - S5
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.28049
DO  - doi:10.1002/pbc.28049
SP  - e28049
PY  - 2019
ER  - 

AU  - Harmon, William
C7  - pp. 1370-1389
TI  - Pediatric Kidney Transplantation
SN  - 9781118870143
UR  - https://doi.org/10.1002/9781118873434.ch113
DO  - doi:10.1002/9781118873434.ch113
SP  - 1370-1389
KW  - clinical research/practice
KW  - kidney transplantation/nephrology
KW  - complication
KW  - graft survival
KW  - patient survival
KW  - recipient selection
KW  - surgical technique
PY  - 2019
AB  - Summary Kidney transplantation is in children, as in adults, the preferred treatment for most causes of end stage renal disease. However, the indications bringing children to require transplantation differ from those of adults, as do the co-morbidities. Additionally, the pediatric population offers unique technical challenges related to congenital anomalies, social support concerns and issues of non-adherence, and nuances of immune, physical and emotional maturity that clearly distinguishes the practice of pediatric transplantation from adult transplantation. This chapter will provide an overview of pediatric kidney transplantation with particular attention directed toward those aspects of the patient population served that define the field.
ER  - 

TY  - JOUR
TI  - 42nd Annual Meeting of the Japanese Society of Neuropathology
JO  - Neuropathology
VL  - 21
IS  - 2
SN  - 9781118870143
UR  - https://doi.org/10.1046/j.1440-1789.2001.00212.x
DO  - doi:10.1046/j.1440-1789.2001.00212.x
SP  - A1
EP  - A55
PY  - 2001
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 26
IS  - S1
SN  - 9781118870143
UR  - https://doi.org/10.1111/ene.14017
DO  - doi:10.1111/ene.14017
SP  - 16
EP  - 111
PY  - 2019
ER  - 

TY  - JOUR
AU  - Wise, Sarah K.
AU  - Lin, Sandra Y.
AU  - Toskala, Elina
AU  - Orlandi, Richard R.
AU  - Akdis, Cezmi A.
AU  - Alt, Jeremiah A.
AU  - Azar, Antoine
AU  - Baroody, Fuad M.
AU  - Bachert, Claus
AU  - Canonica, G. Walter
AU  - Chacko, Thomas
AU  - Cingi, Cemal
AU  - Ciprandi, Giorgio
AU  - Corey, Jacquelynne
AU  - Cox, Linda S.
AU  - Creticos, Peter Socrates
AU  - Custovic, Adnan
AU  - Damask, Cecelia
AU  - DeConde, Adam
AU  - DelGaudio, John M.
AU  - Ebert, Charles S.
AU  - Eloy, Jean Anderson
AU  - Flanagan, Carrie E.
AU  - Fokkens, Wytske J.
AU  - Franzese, Christine
AU  - Gosepath, Jan
AU  - Halderman, Ashleigh
AU  - Hamilton, Robert G.
AU  - Hoffman, Hans Jürgen
AU  - Hohlfeld, Jens M.
AU  - Houser, Steven M.
AU  - Hwang, Peter H.
AU  - Incorvaia, Cristoforo
AU  - Jarvis, Deborah
AU  - Khalid, Ayesha N.
AU  - Kilpeläinen, Maritta
AU  - Kingdom, Todd. T.
AU  - Krouse, Helene
AU  - Larenas-Linnemann, Desiree
AU  - Laury, Adrienne M.
AU  - Lee, Stella E.
AU  - Levy, Joshua M.
AU  - Luong, Amber U.
AU  - Marple, Bradley F.
AU  - McCoul, Edward D.
AU  - McMains, K. Christopher
AU  - Melén, Erik
AU  - Mims, James W.
AU  - Moscato, Gianna
AU  - Mullol, Joaquim
AU  - Nelson, Harold S.
AU  - Patadia, Monica
AU  - Pawankar, Ruby
AU  - Pfaar, Oliver
AU  - Platt, Michael P.
AU  - Reisacher, William
AU  - Rondón, Carmen
AU  - Rudmik, Luke
AU  - Ryan, Matthew
AU  - Sastre, Joaquin
AU  - Schlosser, Rodney J.
AU  - Settipane, Russell A.
AU  - Sharma, Hemant P.
AU  - Sheikh, Aziz
AU  - Smith, Timothy L.
AU  - Tantilipikorn, Pongsakorn
AU  - Tversky, Jody R.
AU  - Veling, Maria C.
AU  - Wang, De Yun
AU  - Westman, Marit
AU  - Wickman, Magnus
AU  - Zacharek, Mark
TI  - International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
JO  - International Forum of Allergy & Rhinology
JA  - Int Forum Allergy Rhinol.
VL  - 8
IS  - 2
SN  - 9781118870143
UR  - https://doi.org/10.1002/alr.22073
DO  - doi:10.1002/alr.22073
SP  - 108
EP  - 352
KW  - allergen extract
KW  - allergy
KW  - allergen immunotherapy
KW  - allergic rhinitis
KW  - antihistamine
KW  - asthma
KW  - atopic dermatitis
KW  - avoidance
KW  - biologic
KW  - cockroach
KW  - conjunctivitis
KW  - consensus
KW  - corticosteroid
KW  - cough
KW  - cromolyn
KW  - decongestant
KW  - eosinophilic esophagitis
KW  - environment
KW  - epicutaneous immunotherapy
KW  - epidemiology
KW  - evidence-based medicine
KW  - food allergy
KW  - genetics
KW  - house dust mite
KW  - IgE
KW  - immunoglobulin E
KW  - immunotherapy
KW  - inhalant allergy
KW  - leukotriene
KW  - microbiome
KW  - occupational rhinitis
KW  - omalizumab
KW  - pathophysiology
KW  - perennial
KW  - pet dander
KW  - pollen
KW  - probiotic
KW  - quality of life
KW  - rhinitis
KW  - rhinosinusitis
KW  - risk factor
KW  - saline
KW  - seasonal
KW  - sensitization
KW  - sinusitis
KW  - sleep
KW  - socioeconomic
KW  - specific IgE
KW  - subcutaneous immunotherapy
KW  - sublingual immunotherapy
KW  - systematic review
KW  - rhinitis
KW  - total IgE
KW  - transcutaneous immunotherapy
KW  - validated survey
PY  - 2018
AB  - Background Critical examination of the quality and validity of available allergic rhinitis (AR) literature is necessary to improve understanding and to appropriately translate this knowledge to clinical care of the AR patient. To evaluate the existing AR literature, international multidisciplinary experts with an interest in AR have produced the International Consensus statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR). Methods Using previously described methodology, specific topics were developed relating to AR. Each topic was assigned a literature review, evidence-based review (EBR), or evidence-based review with recommendations (EBRR) format as dictated by available evidence and purpose within the ICAR:AR document. Following iterative reviews of each topic, the ICAR:AR document was synthesized and reviewed by all authors for consensus. Results The ICAR:AR document addresses over 100 individual topics related to AR, including diagnosis, pathophysiology, epidemiology, disease burden, risk factors for the development of AR, allergy testing modalities, treatment, and other conditions/comorbidities associated with AR. Conclusion This critical review of the AR literature has identified several strengths; providers can be confident that treatment decisions are supported by rigorous studies. However, there are also substantial gaps in the AR literature. These knowledge gaps should be viewed as opportunities for improvement, as often the things that we teach and the medicine that we practice are not based on the best quality evidence. This document aims to highlight the strengths and weaknesses of the AR literature to identify areas for future AR research and improved understanding.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Psycho-Oncology
JA  - Psycho‐Oncology
VL  - 5
IS  - 2
SN  - 9781118870143
UR  - https://doi.org/10.1002/pon.2960050202
DO  - doi:10.1002/pon.2960050202
SP  - 143
EP  - 211
PY  - 1996
ER  - 

TY  - JOUR
TI  - Wednesday Posters
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 16
IS  - s2
SN  - 9781118870143
UR  - https://doi.org/10.1111/codi.12644_2
DO  - doi:10.1111/codi.12644_2
SP  - 159
EP  - 203
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Nephrology
VL  - 13
IS  - s1
SN  - 9781118870143
UR  - https://doi.org/10.1111/j.1440-1797.2008.00954.x
DO  - doi:10.1111/j.1440-1797.2008.00954.x
SP  - A24
EP  - A91
PY  - 2008
ER  - 

TY  - JOUR
TI  - Short Communications
JO  - European Journal of Neurology
VL  - 17
IS  - s3
SN  - 9781118870143
UR  - https://doi.org/10.1111/j.1468-1331.2010.03231.x
DO  - doi:10.1111/j.1468-1331.2010.03231.x
SP  - 20
EP  - 71
PY  - 2010
ER  - 

AU  - Koestner, A.
AU  - Higgins, R. J.
C7  - pp. 697-738
TI  - Tumors of the Nervous System
SN  - 9780813826523
UR  - https://doi.org/10.1002/9780470376928.ch14
DO  - doi:10.1002/9780470376928.ch14
SP  - 697-738
KW  - nervous system
KW  - primary neoplasms
KW  - central nervous system
KW  - peripheral nervous system
KW  - veterinary medical and human medical specialists
PY  - 2010
AB  - Summary This chapter contains section titled: Introduction Primary Tumors of the Central Nervous System Primary Tumors of the Peripheral Nervous System Metastatic Tumors of the Central Nervous System
ER  - 

TY  - JOUR
TI  - Poster presentations
JO  - Journal of Veterinary Pharmacology and Therapeutics
VL  - 32
IS  - s1
SN  - 9780813826523
UR  - https://doi.org/10.1111/j.1365-2885.2009.01091.x
DO  - doi:10.1111/j.1365-2885.2009.01091.x
SP  - 129
EP  - 265
PY  - 2009
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 107
IS  - s1
SN  - 9780813826523
UR  - https://doi.org/10.1111/vox.12153
DO  - doi:10.1111/vox.12153
SP  - 1
EP  - 56
PY  - 2014
ER  - 

AU  - Dutta, Anand S.
C7  - pp. 1-80
TI  - Discovery of New Medicines
SN  - 9781405180351
UR  - https://doi.org/10.1002/9781444317800.ch1
DO  - doi:10.1002/9781444317800.ch1
SP  - 1-80
KW  - discovery of new medicines
KW  - understanding disease processes and mechanisms in controlling disease
KW  - severe acute respiratory syndrome (SARS)
KW  - new infectious diseases - hepatitis C, human herpes virus-6, -7 and -8 and bird flu (H5N1 virus)
KW  - underlying causes of diseases - selective and less toxic drugs
KW  - market needs and changing disease patterns
KW  - new technology impact on drug discovery
KW  - combinatorial chemistry and high-throughput screening
KW  - enzymes and enzyme inhibitors
KW  - DNA and RNA based therapeutics
PY  - 2014
AB  - Summary This chapter contains sections titled: Introduction Market needs and changing disease patterns Medicines marketed in the years 2004?2007 Historical aspects Impact of new technology on drug discovery Examples of drug discovery Enzymes and enzyme inhibitors Protein?protein interaction inhibitors Protein antibody and vaccine therapeutics DNA and RNA based therapeutics Conclusions References
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - Clinical Microbiology and Infection
VL  - 16
IS  - s2
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1469-0691.2010.03238.x
DO  - doi:10.1111/j.1469-0691.2010.03238.x
SP  - S1
EP  - S132
PY  - 2010
ER  - 

TY  - JOUR
TI  - Orals
JO  - Vox Sanguinis
VL  - 101
IS  - s2
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1423-0410.2011.01545.x
DO  - doi:10.1111/j.1423-0410.2011.01545.x
SP  - 1
EP  - 38
PY  - 2011
ER  - 

TY  - JOUR
TI  - Mechanisms of Injury
JO  - Hepatology
JA  - Hepatology
VL  - 58
IS  - S1
SN  - 9781405180351
UR  - https://doi.org/10.1002/hep.26846
DO  - doi:10.1002/hep.26846
SP  - 447A
EP  - 455A
PY  - 2013
ER  - 

TY  - JOUR
AU  - Armitage, Gary C.
TI  - Periodontal Diseases: Diagnosis
JO  - Annals of Periodontology
JA  - Annals of Periodontology
VL  - 1
IS  - 1
SN  - 9781405180351
UR  - https://doi.org/10.1902/annals.1996.1.1.37
DO  - doi:10.1902/annals.1996.1.1.37
SP  - 37
EP  - 215
PY  - 1996
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - HPB
VL  - 13
IS  - s1
SN  - 9781405180351
UR  - https://doi.org/10.1111/j.1477-2574.2011.00291.x
DO  - doi:10.1111/j.1477-2574.2011.00291.x
SP  - 1
EP  - 77
PY  - 2011
ER  - 

TY  - JOUR
TI  - Oral Presentation (As Appear in the Program)
JO  - American Journal of Reproductive Immunology
JA  - Am J Reprod Immunol
VL  - 78
IS  - S1
SN  - 9781405180351
UR  - https://doi.org/10.1111/aji.12736
DO  - doi:10.1111/aji.12736
SP  - 35
EP  - 44
PY  - 2017
ER  - 

TY  - JOUR
AU  - Lenssen, Polly
AU  - Bruemmer, Barbara
AU  - Aker, Saundra N.
AU  - McDonald, George B.
TI  - Nutrient Support in Hematopoietic Cell Transplantation
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 25
IS  - 4
SN  - 9781405180351
UR  - https://doi.org/10.1177/0148607101025004219
DO  - doi:10.1177/0148607101025004219
SP  - 219
EP  - 228
PY  - 2001
AB  - High-dose cytoreduction and hematopoietic stem cell infusion form the basis for treatment of hematologic cancers, defects or failure of hematopoiesis, and some solid tumors. As an antitumor therapy, allogeneic hematopoietic cell transplantation (HCT) is superior to autologous HCT by induction of a graft-us-tumor effect. However, recipients of allografts suffer higher transplant-related mortality owing to graft-us-host disease (GVHD). Nutrition support research must recognize that HCT is a heterogeneous modality whose short and long-term outcomes are affected by transplant type, preparative regimens, diagnosis, disease stage, age, and nutritional status. The field of HCT will diversify further as lower dose cytoreduction and mixed chimerism grafts allow expansion of the technique to older patients and to other diseases. (journal of Parenteral and Enteral Nutrition 25:219?228, 2001)
ER  - 
